Transcatheter aortic valve replacement with the Portico valve: One-year results of the early Canadian experience

Gidon Y. Perlman, Anson Cheung, Eric Dumont, Dion Stub, Danny Dvir, Maria Del Trigo, Marc Pelletier, Sami Alnasser, Jian Ye, David Wood, Christopher Thompson, Philipp Blanke, Jonathon Leipsic, Michael A. Seidman, Heather LeBlanc, Christopher E. Buller, Josep Rodés-Cabau, John G. Webb

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)


Aims: The aim of this study was to examine the short-and medium-term outcomes of transcatheter aortic valve replacement (TAVR) with the self-expanding and repositionable Portico valve (St. Jude Medical, St. Paul, MN, USA). Methods and results: A total of 57 patients underwent TAVR with the Portico valve between March 2012 and August 2014, representing the first-in-human experience and the entire early experience in Canada. Patients were followed up at 30 days and one year with repeat echocardiography and clinical review. Patients were 80.8±7.3 years of age, and the Society of Thoracic Surgeons predicted risk of mortality was 7.7±5.7%. All patients had a valve implanted and four patients (7%) required a second valve. At 30 days, there were two deaths (3.5%), three disabling strokes (5.3%), and new pacemakers in five (8.8%) patients. Echocardiography revealed moderate/severe aortic regurgitation in two patients (3.6%). At one year, survival was 84.2% and echocardiographic findings were unchanged. Conclusions: Transcatheter aortic valve replacement with the repositionable Portico valve provides satisfactory short-and medium-term haemodynamic and clinical results.

Original languageEnglish
Pages (from-to)1653-1659
Number of pages7
Issue number13
Publication statusPublished - 2017
Externally publishedYes


  • Aortic valve stenosis
  • Portico valve
  • Transcatheter aortic valve replacement

Cite this